BMPR2 and pulmonary arterial hypertension: We recommend a previously completed or ongoing trial or registration of PAH should be analyzed in a gender subgroup analysis of patients with BMPR2 mutations to determine whether gender differences in BMPR2 mutations are associated with gender differences in disease severity among this patient population.